A Review of Trastuzumab-Based Therapy in Patients with HER2-positive Metastatic Breast Cancer

被引：0
|
作者：
Church, David N. [1 ]
Price, Chris G. A. [2 ]
机构：
[1] Univ Oxford, John Racliffe Hosp, Weatherall Inst Mol Med, Headley Way, Oxford OX3 9DS, England
[2] Bristol Haematol & Oncol Ctr, Bristol BS1 8ED, Avon, England
来源：
CLINICAL MEDICINE INSIGHTS-THERAPEUTICS | 2009年 / 1卷
关键词：
breast cancer; trastuzumab; metastatic; ERBB2; HER2;
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The ERBB2 or HER2 receptor is overexpressed in 25% of breast cancers and is associated with poor prognosis. Trastuzumab, a monoclonal antibody targeting HER2 has been demonstrated to improve survival when combined with chemotherapy for the treatment of HER2 overexpressing metastatic breast cancer (MBC). Further studies have endeavoured to clarify the optimum chemotherapy regimen in combination with trastuzumab for MBC and its use together with novel biological agents. This review summarises these data together with preclinical studies exploring the mechanism of trastuzumab action and causes of drug resistance. The frequent incidence of brain metastases in patients on trastuzumab is highlighted, and data on the continuation of trastuzumab following CNS and non-CNS progression reviewed.
引用
收藏
页码：557 / 570
页数：14
相关论文
共 50 条
  • [41] Targeted therapy in HER2-positive metastatic breast cancer: a review of the literature
    Zhu, X.
    Verma, S.
    CURRENT ONCOLOGY, 2015, 22 : S19 - S28
  • [42] Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancer
    Iwata, Hiroji
    Masuda, Norikazu
    Kim, Sung-Bae
    Inoue, Kenichi
    Rai, Yoshiaki
    Fujita, Takashi
    Chiu, Joanne
    Ohtani, Shoichiro
    Takahashi, Masato
    Miyaki, Toshiko
    Lu, Yen-Shen
    Xu, Binghe
    Yap, Yoon Sim
    Bustam, Anita
    Yao, Bin
    Zhang, Bo
    Bryce, Richard
    Chan, Arlene
    FUTURE ONCOLOGY, 2019, 15 (21) : 2489 - 2501
  • [43] Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer
    Mariani, Gabriella
    Fasolo, Angelica
    De Benedictis, Elena
    Gianni, Luca
    NATURE CLINICAL PRACTICE ONCOLOGY, 2009, 6 (02): : 93 - 104
  • [44] Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers
    Baldassarre, Tomas
    Truesdell, Peter
    Craig, Andrew W.
    BREAST CANCER RESEARCH, 2017, 19
  • [45] Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer
    Kawajiri, Hidemi
    Takashima, Tsutomu
    Kashiwagi, Shinichiro
    Noda, Satoru
    Onoda, Naoyoshi
    Hirakawa, Kosei
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (01) : 17 - 26
  • [46] Trastuzumab for HER2-Positive Metastatic Breast Cancer: Clinical and Economic Considerations
    Jeyakumar, Alwin
    Younis, Tallal
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2012, 6
  • [47] Very long response with trastuzumab for metastatic Her2-positive breast cancer
    Lai-Tiong, F.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2018, 39 (06) : 1002 - 1003
  • [48] Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure
    Antonarelli, G.
    Corti, C.
    Salimbeni, B. T.
    Tarantino, P.
    Zagami, P.
    Marra, A.
    Trapani, D.
    Tolaney, S.
    Cortes, J.
    Curigliano, G.
    ESMO OPEN, 2023, 8 (04)
  • [49] The role of trastuzumab in the management of HER2-positive metastatic breast cancer: an updated review
    Tokuda, Yutaka
    Suzuki, Yasuhiro
    Saito, Yuki
    Umemura, Shinobu
    BREAST CANCER, 2009, 16 (04) : 295 - 300
  • [50] The role of trastuzumab in the management of HER2-positive metastatic breast cancer: an updated review
    Yutaka Tokuda
    Yasuhiro Suzuki
    Yuki Saito
    Shinobu Umemura
    Breast Cancer, 2009, 16 : 295 - 300
12345